Workflow
Qualigen Therapeutics(QLGN)
icon
Search documents
Qualigen Therapeutics(QLGN) - 2020 Q1 - Quarterly Report
2020-05-01 21:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 001-37428 RITTER PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) (State or other ...
Qualigen Therapeutics(QLGN) - 2019 Q4 - Annual Report
2020-03-31 21:27
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37428 RITTER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 26-3474527 (State or other jurisdiction of incorporation or orga ...
Qualigen Therapeutics(QLGN) - 2019 Q3 - Quarterly Report
2019-11-14 02:58
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 001-37428 RITTER PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) (State or ot ...
Qualigen Therapeutics(QLGN) - 2019 Q2 - Quarterly Report
2019-08-14 21:14
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 001-37428 RITTER PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) (State or other j ...
Qualigen Therapeutics(QLGN) - 2019 Q1 - Quarterly Report
2019-05-15 20:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 001-37428 RITTER PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) (State or other ...
Qualigen Therapeutics(QLGN) - 2018 Q4 - Annual Report
2019-04-01 10:21
For the fiscal year ended December 31, 2018 or UNITED STATES SECURITIES AND EXCHANGE COMMISSION [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 Commission File Number 001-37428 RITTER PHARMACEUTICALS, INC. FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Title of Each Class Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share NASDAQ Capital Market Sec ...